| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYL9 |
| Uniprot No | P24844 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-172aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MSSKRAKAKT TKKRPQRATS NVFAMFDQSQ IQEFKEAFNM IDQNRDGFID KEDLHDMLAS LGKNPTDEYL EGMMSEAPGP INFTMFLTMF GEKLNGTDPE DVIRNAFACF DEEASGFIHE DHLRELLTTM GDRFTDEEVD EMYREAPIDK KGNFNYVEFT RILKHGAKDK DD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYL9重组蛋白的参考文献及其摘要概括：
1. **《MYL9重组蛋白在肿瘤细胞迁移中的功能研究》 - Zhang et al.**
摘要：该研究通过表达纯化MYL9重组蛋白，发现其通过调控肌动蛋白-肌球蛋白相互作用促进肿瘤细胞的迁移和侵袭，提示MYL9在癌症转移中的潜在作用。
2. **《重组MYL9对血管平滑肌收缩的调控机制》 - Lee et al.**
摘要：利用MYL9重组蛋白进行体外实验，揭示其磷酸化状态通过Rho/ROCK信号通路调节血管平滑肌细胞收缩，为高血压治疗提供分子机制依据。
3. **《MYL9磷酸化位点突变体的功能表征》 - Chen et al.**
摘要：通过构建MYL9重组蛋白的磷酸化位点突变体，证实Ser19和Thr18位点的修饰影响细胞骨架重排，进而调控内皮屏障功能及炎症反应。
4. **《MYL9基因敲除模型中重组蛋白的功能挽救实验》 - Saito et al.**
摘要：在MYL9敲除细胞中导入重组MYL9蛋白，恢复了细胞定向迁移能力，验证了其在伤口愈合和胚胎发育中的关键角色。
注：以上内容为示例性概括，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
MYL9 (Myosin Light Chain 9) is a regulatory protein involved in cellular contractility and motility, primarily functioning as a critical component of non-muscle myosin II (NMII) complexes. It belongs to the myosin light chain family, which modulates the ATPase activity of myosin heavy chains, enabling actomyosin interactions essential for cytoskeletal dynamics. MYL9 is encoded by the MYL9 gene located on human chromosome 20q11.23 and is expressed in various tissues, particularly in smooth muscle cells, endothelial cells, and platelets. Its phosphorylation status, regulated by kinases like Rho-associated protein kinase (ROCK) and myosin light chain kinase (MLCK), dictates myosin II assembly and contractile force generation, influencing processes such as cell adhesion, migration, and vascular tone regulation.
Recombinant MYL9 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional protein for research applications. It typically retains post-translational modification sites, enabling studies on phosphorylation-dependent signaling pathways. Researchers utilize recombinant MYL9 to investigate its role in pathological conditions, including cancer metastasis (via tumor cell invasion), cardiovascular diseases (e.g., hypertension, atherosclerosis), and thrombotic disorders (due to platelet activation mechanisms). Its interaction with cytoskeletal proteins and involvement in endothelial barrier integrity also make it relevant in inflammation and angiogenesis studies. Recombinant MYL9 serves as a tool for drug screening, structural analysis, and antibody development, offering insights into targeting myosin-mediated pathways for therapeutic interventions.
×
